<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536443</url>
  </required_header>
  <id_info>
    <org_study_id>COMMIT015</org_study_id>
    <nct_id>NCT02536443</nct_id>
  </id_info>
  <brief_title>Contemporary Modalities in Treatment of Heart Failure</brief_title>
  <acronym>COMMIT-HF</acronym>
  <official_title>Contemporary Modalities in Treatment of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silesian Centre for Heart Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silesian Centre for Heart Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Contemporary Modalities In Treatment of Heart Failure Registry (COMMIT-HF) is an
      observational study on an all-comer systolic heart failure population hospitalized in a
      highly specialized cardiovascular center. The aim of the study is to assess the clinical
      characteristics, treatment modalities and prognosis in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Contemporary Modalities In Treatment of Heart Failure Registry (COMMIT-HF) is a
      single-center observational study that is underway in the 3rd Chair and Department of
      Cardiology of Silesian Center for Heart Diseases in Zabrze, Poland. Data collection is
      patient-based (not event-based).

      The main objective of the COMMIT-HF Registry is to clarify the overall clinical
      characteristics of systolic heart failure patients, their demographics and clinical profile,
      current management, in-hospital outcomes and long-term follow-up, with regard to the
      administered treatment.

      The study population is formed by all-comer patients hospitalized in cardiology wards and
      intensive cardiac care units with a diagnosis of systolic heart failure. For the purpose of
      this study heart failure is defined as a set of symptoms resulting from myocardial systolic
      function impairment, confirmed in resting transthoracic echocardiography with left
      ventricular ejection fraction (LVEF) ≤35%. Patients with acute coronary syndromes are
      excluded from the analysis.

      Complete patient demographics; medical history, complete hospitalization data (diagnostic and
      therapeutic) and in-hospital results are collected in an electronic form by the attending
      physician. The patients are under constant follow-up for all cause mortality and major
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Number of participants with reported deaths from any cause</measure>
    <time_frame>From date of inclusion until the date of death from any cause, assessed up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reported heart-failure related rehospitalization</measure>
    <time_frame>From date of inclusion until the date of first event, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reported myocardial infarction</measure>
    <time_frame>From date of inclusion until the date of first event, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reported cerebrovascular insult</measure>
    <time_frame>From date of inclusion until the date of first event, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants to undergo mechanical circulatory support implantation</measure>
    <time_frame>From date of inclusion until the date implantation, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants to undergo orthotopic heart transplantation</measure>
    <time_frame>From date of inclusion until the date transplantation, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is formed by all-comer patients hospitalized in cardiology wards and
        intensive cardiac care units with a diagnosis of systolic heart failure. For the purpose of
        this study heart failure is defined as a set of symptoms resulting from myocardial systolic
        function impairment, confirmed in resting transthoracic echocardiography with left
        ventricular ejection fraction (LVEF) ≤35%.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptom based diagnosis of heart failure

          -  echocardiographically confirmed impaired left ventricular ejection fraction ≤35%.

        Exclusion Criteria:

          -  acute coronary syndrome on admission

          -  ≥ 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariusz Gasior, Prof., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>3rd Chair and Department of Cardiology, Silesian Center for Heart Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lukasz Pyka, MD</last_name>
    <role>Study Chair</role>
    <affiliation>3rd Chair and Department of Cardiology, Silesian Center for Heart Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukasz Pyka, MD</last_name>
    <phone>+48502412336</phone>
    <email>pyka@vp.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>SIlesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <state>Silesia</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Pyka, MD</last_name>
      <phone>+48502412336</phone>
      <email>pyka@vp.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Gąsior M, Pyka Ł, Gorol J, Hawranek M, Tajstra M, Słonka G, Kurek A, Krajewski A, Rozentryt P, Gierlotka M, Lekston A, Zembala M, Poloński L. COnteMporary Modalities In Treatment of Heart Failure: a report from the COMMIT-HF registry. Kardiol Pol. 2016;74(6):523-8. doi: 10.5603/KP.a2015.0224. Epub 2015 Nov 24.</citation>
    <PMID>26596896</PMID>
  </results_reference>
  <results_reference>
    <citation>Pyka Ł, Hawranek M, Tajstra M, Gorol J, Lekston A, Gąsior M. Complete percutaneous revascularisation feasibility in ischaemic heart failure is related to improved outcomes: insights from the COMMIT-HF registry. Kardiol Pol. 2017;75(5):453-461. doi: 10.5603/KP.a2017.0018. Epub 2017 Feb 2.</citation>
    <PMID>28150287</PMID>
  </results_reference>
  <results_reference>
    <citation>Kurek A, Tajstra M, Gadula-Gacek E, Buchta P, Skrzypek M, Pyka L, Wasiak M, Swietlinska M, Hawranek M, Polonski L, Gasior M, Kosiuk J. Impact of Remote Monitoring on Long-Term Prognosis in Heart Failure Patients in a Real-World Cohort: Results From All-Comers COMMIT-HF Trial. J Cardiovasc Electrophysiol. 2017 Apr;28(4):425-431. doi: 10.1111/jce.13174. Epub 2017 Mar 7.</citation>
    <PMID>28176442</PMID>
  </results_reference>
  <results_reference>
    <citation>Wasilewski J, Pyka Ł, Hawranek M, Tajstra M, Skrzypek M, Wasiak M, Suliga K, Bujak K, Gąsior M. Prognostic value of red blood cell distribution width in patients with left ventricular systolic dysfunction: Insights from the COMMIT-HF registry. Cardiol J. 2017 Mar 29. doi: 10.5603/CJ.a2017.0037. [Epub ahead of print]</citation>
    <PMID>28353308</PMID>
  </results_reference>
  <results_reference>
    <citation>Wasilewski J, Pyka Ł, Hawranek M, Osadnik T, Kurek A, Skrzypek M, Niedziela J, Desperak P, Kułaczkowska Z, Brzezina M, Krawczyk M, Gąsior M. Prognostic value of neutrophil‑to‑lymphocyte ratio in predicting long-term mortality in patients with ischemic and nonischemic heart failure. Pol Arch Med Wewn. 2016;126(3):166-73. doi: 10.20452/pamw.3316. Epub 2016 Mar 18.</citation>
    <PMID>26991886</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Silesian Centre for Heart Diseases</investigator_affiliation>
    <investigator_full_name>Mariusz Gasior</investigator_full_name>
    <investigator_title>Professor, PhD</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>prognosis</keyword>
  <keyword>clinical characteristics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

